Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 20/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764651 | 0.86 | OGA (0.65) | OGA | |
| SCHEMBL21764419 | 0.86 | OGA (0.70) | OGA | |
| SCHEMBL21753263 | 0.84 | OGA (0.69) | OGA | |
| SCHEMBL20482182 | 0.83 | OGA (0.70) | OGA | |
| SCHEMBL21764471 | 0.82 | OGA (1.00) | OGA | |
| SCHEMBL21762016 | 0.81 | OGA (0.49) | OGA | |
| SCHEMBL21762023 | 0.81 | OGA (0.49) | OGA | |
| SCHEMBL20482016 | 0.81 | OGA (0.56) | OGA | |
| SCHEMBL21762195 | 0.81 | OGA (0.49) | OGA | |
| SCHEMBL20779912 | 0.80 | OGA (0.61) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12195455-B2 | Succinate and fumarate acid addition salts of piperazine derivatives | ASCENEURON SA (CH) | 2025-01-14 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| EP-3841093-B1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-3841093-B1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2022-03-01 | — | — | US | disclosed |
| CN-113166083-A | Succinate and fumarate acid addition salts of piperazine derivatives as glycosidase inhibitors | 阿森纽荣股份公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-07-01 | — | — | US | disclosed |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | ASCENEURON SA (CH) | 2021-07-01 | — | — | US | disclosed |
| EP-3841093-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | Asceneuron SA (CH) | 2021-06-30 | — | — | EP | disclosed |
| WO-2020039030-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039030-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES USEFUL AS GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| CN-110770226-A | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018153508-A2 | SULFOXIMINE GLYCOSIDASE INHIBITORS | Asceneuron S.A. (CH) | 2018-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | OGA 57/4885 |
| US-12195455-B2 | Succinate and fumarate acid addition salts of piperazine derivatives | FH, SDHA, SDHB | OGA 471/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | OGA 57/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | OGA 42/4885 |
| US-20210198250-A1 | SUCCINATE AND FUMARATE ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES | SDHA, SDHB, SORD | OGA 614/4885 |
| US-11261183-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | OGA 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.